These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://jadatvcw431835.blogcudinti.com/39259112/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide